333 related articles for article (PubMed ID: 32226528)
1. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.
Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM
Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528
[No Abstract] [Full Text] [Related]
2. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.
Zhou X; Chen X; Cai JJ; Chen LZ; Gong YS; Wang LX; Gao Z; Zhang HQ; Huang WJ; Zhou H
Drug Des Devel Ther; 2015; 9():4599-611. PubMed ID: 26316699
[TBL] [Abstract][Full Text] [Related]
3. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.
Jelinic M; Leo CH; Post Uiterweer ED; Sandow SL; Gooi JH; Wlodek ME; Conrad KP; Parkington H; Tare M; Parry LJ
FASEB J; 2014 Jan; 28(1):275-87. PubMed ID: 24036884
[TBL] [Abstract][Full Text] [Related]
4. Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins.
Sarwar M; Samuel CS; Bathgate RA; Stewart DR; Summers RJ
Br J Pharmacol; 2015 Feb; 172(4):1005-19. PubMed ID: 25297987
[TBL] [Abstract][Full Text] [Related]
5. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease.
Samuel CS; Bodaragama H; Chew JY; Widdop RE; Royce SG; Hewitson TD
Hypertension; 2014 Aug; 64(2):315-22. PubMed ID: 24866131
[TBL] [Abstract][Full Text] [Related]
6. Increase of cortical cerebral blood flow and further cerebral microcirculatory effects of Serelaxin in a sheep model.
Bischoff SJ; Schmidt M; Lehmann T; Irintchev A; Schubert H; Jung C; Schwab M; Huber O; Matziolis G; Schiffner R
Am J Physiol Heart Circ Physiol; 2016 Sep; 311(3):H613-20. PubMed ID: 27402664
[TBL] [Abstract][Full Text] [Related]
7. Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.
Sarwar M; Samuel CS; Bathgate RA; Stewart DR; Summers RJ
Br J Pharmacol; 2016 Feb; 173(3):484-96. PubMed ID: 26493539
[TBL] [Abstract][Full Text] [Related]
8. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
Grampp S; Goppelt-Struebe M
Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
[TBL] [Abstract][Full Text] [Related]
9. Serelaxin inhibits differentiation and fibrotic behaviors of cardiac fibroblasts by suppressing ALK-5/Smad2/3 signaling pathway.
Wu XP; Wang HJ; Wang YL; Shen HR; Tan YZ
Exp Cell Res; 2018 Jan; 362(1):17-27. PubMed ID: 28987540
[TBL] [Abstract][Full Text] [Related]
10. H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor.
Hossain MA; Man BC; Zhao C; Xu Q; Du XJ; Wade JD; Samuel CS
Biochemistry; 2011 Mar; 50(8):1368-75. PubMed ID: 21229994
[TBL] [Abstract][Full Text] [Related]
11. Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.
Wolf VL; Phillips TL; Taylor EB; Sasser JM; Ryan MJ
Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H234-H242. PubMed ID: 31125285
[TBL] [Abstract][Full Text] [Related]
12. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.
Snowdon VK; Lachlan NJ; Hoy AM; Hadoke PW; Semple SI; Patel D; Mungall W; Kendall TJ; Thomson A; Lennen RJ; Jansen MA; Moran CM; Pellicoro A; Ramachandran P; Shaw I; Aucott RL; Severin T; Saini R; Pak J; Yates D; Dongre N; Duffield JS; Webb DJ; Iredale JP; Hayes PC; Fallowfield JA
PLoS Med; 2017 Feb; 14(2):e1002248. PubMed ID: 28245243
[TBL] [Abstract][Full Text] [Related]
13. Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats.
Wang D; Luo Y; Myakala K; Orlicky DJ; Dobrinskikh E; Wang X; Levi M
Sci Rep; 2017 Aug; 7(1):9793. PubMed ID: 28851937
[TBL] [Abstract][Full Text] [Related]
14. Prolyl 4-Hydroxylase Domain Protein 3 Overexpression Improved Obstructive Sleep Apnea-Induced Cardiac Perivascular Fibrosis Partially by Suppressing Endothelial-to-Mesenchymal Transition.
Zhang GH; Yu FC; Li Y; Wei Q; Song SS; Zhou FP; Tong JY
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051216
[TBL] [Abstract][Full Text] [Related]
15. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue.
Aragón-Herrera A; Feijóo-Bandín S; Abella V; Álvarez L; Roselló-Lletí E; Portolés M; Tarazón E; Bigazzi M; Bani D; Gualillo O; González-Juanatey JR; Lago F
Pharmacol Res; 2019 Jun; 144():51-65. PubMed ID: 30954631
[TBL] [Abstract][Full Text] [Related]
16. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists.
Hu X; Myhr C; Huang Z; Xiao J; Barnaeva E; Ho BA; Agoulnik IU; Ferrer M; Marugan JJ; Southall N; Agoulnik AI
Biochemistry; 2016 Mar; 55(12):1772-83. PubMed ID: 26866459
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis.
Xu X; Tan X; Tampe B; Nyamsuren G; Liu X; Maier LS; Sossalla S; Kalluri R; Zeisberg M; Hasenfuss G; Zeisberg EM
Cardiovasc Res; 2015 Mar; 105(3):279-91. PubMed ID: 25616414
[TBL] [Abstract][Full Text] [Related]
18. Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy.
Giam B; Chu PY; Kuruppu S; Smith AI; Horlock D; Murali A; Kiriazis H; Du XJ; Kaye DM; Rajapakse NW
Exp Physiol; 2018 Dec; 103(12):1593-1602. PubMed ID: 30311699
[TBL] [Abstract][Full Text] [Related]
19. ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.
Kocan M; Sarwar M; Ang SY; Xiao J; Marugan JJ; Hossain MA; Wang C; Hutchinson DS; Samuel CS; Agoulnik AI; Bathgate RAD; Summers RJ
Sci Rep; 2017 Jun; 7(1):2968. PubMed ID: 28592882
[TBL] [Abstract][Full Text] [Related]
20. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
